Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05438173 · ClinicalTrials.gov registry record · NA
Bioavailability of EPA/DHA in of Ruby-O and Krill Oil
A NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT05438173: Completed NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
NCT05438173 is a NA study that has completed, run by Midwest Center for Metabolic and Cardiovascular Research. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05438173, a NA study, has completed, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The objective of this study is to assess the relative bioavailability of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in two supplement products in healthy adult men and women.
Primary Outcome
Changes in baseline-adjusted geometric mean ratio for EPA + DHA AUC
Interventions
- DIETARY_SUPPLEMENT EPA + DHA Ruby-O
- DIETARY_SUPPLEMENT EPA + DHA Krill Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2022-09-18 |
| Phase | NA |
What the finished NCT05438173 record still lists
NCT05438173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which EPA + DHA Ruby-O is the first listed.
NCT05438173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05438173 about?
NCT05438173 is a clinical study titled "Bioavailability of EPA/DHA in of Ruby-O and Krill Oil". The objective of this study is to assess the relative bioavailability of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in two supplement products in healthy adult men and women.
What is the current status of trial NCT05438173?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2022-07-11. Estimated completion is 2022-09-18.
What interventions are being tested in trial NCT05438173?
The interventions under investigation include: EPA + DHA Ruby-O (DIETARY_SUPPLEMENT), EPA + DHA Krill Oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05438173?
This trial is sponsored by Midwest Center for Metabolic and Cardiovascular Research, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05438173's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI